Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1361849 + Durvalumab +/- Tremelimumab in NSCLC
NCT03164772Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Dec 2017
- Primary completion
- Oct 2021
- Modality
- Vaccine mRNA, mRNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of CV9202 in non-small cell lung cancer (NSCLC), sponsored by Ludwig Cancer Research. Started Dec 2017; status: completed.
02
Drugs
CV9202
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03164772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164772.